Primary antibody deficiencies (PAD) are the largest group of primary immunodeficiency diseases (PID), affecting patients at various age. Affected individuals are extremely prone to serious and recurrent infections, which can led to tissue damage and premature death. Many patients require regular, life-long prophylactic treatment with immunoglobulin. For years the leading route has been intravenous infusion of immunoglobulin (IVIG). Despite its clinical benefits, IVIG is associated with some inconveniences such as travelling to hospital, difficulties obtaining vein access and systemic side effects. The alternative method to IVIG is subcutaneous immunoglobulin infusion (SCIG), introduced in the 1990s. It has become increasingly popular in recent years. This route does not require venous access, has a really low risk of systemic side effects and improves quality of life. SCIG can be administered either via programmable pump or rapid push infusion. Despite similar effectiveness and risk of adverse events the rapid push route seems to be safe and viable, providing more self-control, treatment flexibility, independence and opportunities for treatment satisfaction. Rapid push immunoglobulin infusion has recently become more popular in the USA and Canada. This route should be considered as an alternative possibility of replacement immunoglobulin therapy in patients with immunodeficiency in Europe.